A group of top Singapore health experts backed the government’s move to approve the Pfizer Inc. and BioNTech SE’s coronavirus vaccine after it conducted an independent review of clinical data on its safety and efficacy.

The vaccine demonstrated a high efficacy rate of 95% and its safety profile is consistent with the high standards set for other registered vaccines used in immunization against other diseases, the committee of experts said in a statement issued by the health ministry on Sunday. It is suitable for use for those aged 16 and above, and is expecting further trial data on other groups, such as pregnant women, the committee said.

The government said separately on Sunday that it’s accepting the committee’s recommendations, and will begin vaccinating health care workers from Dec. 30. The elderly, starting with those aged 70 and above, is targeted to get their shots from February.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook